November 2022 - TinyGems

WednesdayNov 30, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Launches ‘Periscope’ Lidar-Based Sensory System Designed to Increase Pedestrian Safety

70% of total fatalities in urban areas are vulnerable road users As of 2000, a U.S.-based pedestrian was involved in a fatal accident every 81 minutes In conjunction with its technological partners, Cepton has designed a lidar-based road sensor, directed to warn drivers about potential pedestrian activity around a corner 5 seconds before they would otherwise be visible Despite its original intended use as an advanced motion-system tool, the use of lidar technology has far surpassed its original necessities Today, lidar technology is being used within a wide array of initiatives and industries, ranging from security and safety solutions, smart…

TuesdayNov 29, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of blood pressure in the patient population over multiple weeks There is an established link between hypertension and vascular dementia, along with hypertension being twice as frequent in people with diabetes and hypertensive patients being at…

MondayNov 28, 2022 9:00 am

European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment

U.S.-based drug innovator CNS Pharmaceuticals is continuing to advance its global human clinical trial for Berubicin, a potentially pivotal treatment for the incurable brain cancer glioblastomaCNS recently announced its Q3 financial results, including an update on the clinical development that noted the start of patient enrollment and dosing in FranceCNS is also advancing trial sites in the United States, Switzerland, Spain, and Italy, with 29 of 68 anticipated sites currently enrolling patientsThe company expects to provide an interim analysis of the trials in mid-2023 and primary completion in 2024, with ultimate resolution in 2025 The FDA has granted Berubicin Fast Track…

WednesdayNov 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementiaThe animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancementsPrevious independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairmentThe laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023 Lexaria Bioscience (NASDAQ:…

TuesdayNov 22, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial

The National Brain Tumor Society anticipates that more than 13,000 Americans will receive a GBM diagnosis during 2022, accounting for 49.1% of all primary malignant brain tumorsCNS announced the first patient in Europe has been enrolled and dosed in the global trial to evaluate Berubicin for the treatment of GBMBerubicin is a novel anthracycline and the first to appear to cross the blood-brain barrierThe global GBM treatment market is expected to reach a value of $4.2 billion by 2028, driven by the increased approval granted by the FDA for novel GBM treatment therapies CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage…

MondayNov 21, 2022 11:15 am

Cepton, Inc. (NASDAQ: CPTN) to Solidify Its Financial Position With $100 Million Investment from Koito; Forges Ahead Toward Mass-Market Deployment of Its Lidar Technology

Cepton signed binding agreement with established automotive lighting tier 1 supplier Koito for investment of $100 million to bolster its next stage of growthAgreement penned on October 27, 2022, marks the third investment from this long-term automotive Tier 1 partner and existing shareholder since 2020Lidar market expected to grow rapidly to reach $59 billion by 2030; Cepton appears to continue leading as a prominent figure, as it works toward commercialization and mass market deployment of its lidar sensors Following a previously reported letter of intent from Koito Manufacturing Co., Ltd. (TSE:7276), Cepton (NASDAQ: CPTN) has announced that it has entered…

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetesThe company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetesLexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertensionSo far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build on these findings…

WednesdayNov 16, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for researchThe company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiformeThe pivotal trial will study Berubicin’s results compared to the current study of care, LomustineGlobal brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032 Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new cancer cases in…

MondayNov 14, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete ResponseWith GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the diseaseCNS’ management is optimistic about its lead drug candidate and continues to explore the potential treatment of…

FridayNov 11, 2022 10:30 am

Freight Technologies Inc.’s (NASDAQ: FRGT) Capacity Planning Product Poised for Tremendous Growth Following Two-Year Commitment from Shipper Partner

Freight Technologies recently announced receipt of a two-year commitment from Kimberly Clark De Mexico, SAB de CV (“KCM”), that will significantly expand its Fr8PrivateFleet productFr8Tech introduced Fr8PrivateFleet at the end of 2021 through its wholly owned subsidiary Freight App, Inc.capacity The product solves shippers’ need to secure freight over time rather than on a trip-by-trip basis and provides carriers, who can deliver the shipper’s loads based on this criterion, with a steady stream of employment opportunities and revenueThe two-year commitment is set to more than triple Fr8Tech’s capacity in the Fr8PrivateFleet product over three months Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Month: November 2022